

***Fiscal Year 2023 Department of Defense Bone Marrow Failure Research Program (BMFRP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Idea Development Award (IDA)</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number: HT9425-23-BMFRP-IDA</p>	<ul style="list-style-type: none"> • Early Career Investigators: Independent investigators at the level of Assistant Professor (or equivalent), with less than 10 years from their first faculty appointment (or equivalent) by the application submission deadline. • Established Investigator: Independent investigators at or above the level of Associate Professor (or equivalent) or an Assistant Professor (or equivalent) with 10 years or more from their first faculty appointment (or equivalent) by the application submission deadline. 	<ul style="list-style-type: none"> • Supports innovative ideas and high-impact approaches based on scientifically sound evidence to move toward the vision to understand and cure bone marrow failure (BMF) diseases. • Proposed research should have a high probability of revealing new avenues of investigation. • Research project should include a well-formulated, testable hypothesis and a well-developed and articulated research approach. • Must address at least one of the FY23 BMFRP Focus Areas. • Strong BMF research team. • May include relevant preliminary data. • Clinical trials are not allowed. • Translational potential should be considered and described. • <i>Pre-application submission is required; application submission is by invitation only.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$530,000 for direct costs. • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. • The maximum period of performance is 3 years. 	<p>Pre-Application (Preproposal): June 21, 2023 5:00 p.m. Eastern time</p> <p>Application: September 20, 2023 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Investigator-Initiated Research Award (IIRA)</p> <p>Go to:</p> <ul style="list-style-type: none"> Program Announcement General Application Instructions <p>Grants.gov Funding Opportunity Number: HT9425-23-BMFRP-IIRA</p>	<p>Investigators at or above the level of Assistant Professor (or equivalent) by the application submission deadline.</p>	<ul style="list-style-type: none"> • Two funding levels of intent: <ul style="list-style-type: none"> ○ Funding Level 1 (FL): Supports studies that further develop mature ideas, expand upon key discoveries, and have the potential to make significant advances in BMF research and patient care. Correlative studies to existing clinical trials/studies are encouraged. Translational potential should be considered and described. ○ Funding Level 2: Investigational New Drug (IND)-enabling efforts The proposed studies should be empirical in nature, product driven, and focused on the accumulation of data to support an IND application to the U.S. Food and Drug Administration. Applicants are required to identify lead BMF therapy candidate(s), and transition plans should be considered and adequately described. At least one, and no more than three, lead therapeutic candidates must be named at the time of application submission to meet the intent of the FL2 mechanism. • Emphasis on research approach and impact. • Strong BMF research team. • Preliminary data required. • Clinical trials are not allowed. • Must address at least one of the FY23 BMFRP Focus Areas. • Partnering Principal Investigator (PI) Option: Allows two PIs, termed Initiating and Partnering PIs, to collaborate on a single application. • <i>Pre-application submission is required; application submission is by invitation only.</i> 	<p>Funding Level 1:</p> <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$675,000 for direct costs (plus indirect costs). • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 3 years. <p>Funding Level 2: IND-enabling efforts</p> <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$850,000 for direct costs (plus indirect costs). • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 2 years. 	<p>Pre-Application (Preproposal): June 21, 2023 5:00 p.m. Eastern time</p> <p>Application: September 20, 2023 11:59 p.m. Eastern time</p>